Hemodynamic evaluations of patients with small aortic annulus with St. Jude Medical prosthetic heart valve

As the elderly population in Japan increases, senile degenerative aortic valvular disease also tends to increase. These patients often have a small aortic annulus. The problem of “valve-patient-mismatch” occurs when a small prosthesis is inserted into a patient with a small aortic annulus. To avoid annular enlargement after aortic valve replacement (AVR), we tried to use a small-sized St. Jude Medical (SJM) valve. From September 1988 through November 1996, 110 AVR were performed in our institution. In these cases, 30 underwent AVR with a small sized SJM valve (male ≦21 mm, female ≦19 mm). Dobutamine stress echocardiography was performed in 19 patients who had undergone AVR with a small-sized SJM valve. Surgical results were also compared between patients with small aortic annulus and those with normal-sized aortic annulus. Using Doppler echocardiography, pressure gradients (PG), cardiac index (CI), effective orifice area (EOA), and performance index (PI) were calculated at rest and during stress. The mean body surface area (BSA) of patient who had undergone AVR with SJM19A, 19HP and 21A was 1.40, 1.42 and 1.56 m², respectively. With dobutamine stress, heart rates, PG and CI increased significantly. Mean and maximum PG of patients with 19HP (8.0 and 15.4 mmHg at rest, 12.9 and 28.0 mmHg under stress, respectively) and 21A (9.5 and 19.1 mmHg at rest, 16.5 and 35.3 mmHg under stress, respectively) were relatively low. EOA index (EOAI) of patient with 19HP showed the highest values mean 0.93 cm²/m². Pis tended to be higher with HP models than with standard models. The tests were completed without significant side effects such as frequent ventricular arrhythmias. Among the cases with small aortic annulus, there were no operative deaths or hospital deaths. There were also no late deaths, episodes of hemorrhage or thrombosis. Conclusions. In our institution, AVR was peformed safely without any aortic annular enlargement with a small aortic anulus in small BSA patients. Postoperative hemodynamic data obtained by echocardiography were satisfactory for all patients at rest and even during maximum dobutamine stress test.     

Hemodynamic evaluations of patients with small aortic annulus with St. Jude Medical prosthetic heart valve]

As the elderly population in Japan increases, senile degenerative aortic valvular disease also tends to increase. These patients often have a small aortic annulus. The problem of "valve-patient-mismatch" occurs when a small prosthesis is inserted into a patient with a small aortic annulus. To avoid annular enlargement after aortic valve replacement (AVR), we tried to use a small-sized St. Jude Medical (SJM) valve. From September 1988 through November 1996, 110 AVR were performed in our institution. In these cases, 30 underwent AVR with a small sized SJM valve (male < or = 21 mm, female < or = 19 mm). Dobutamine stress echocardiography was performed in 19 patients who had undergone AVR with a small-sized SJM valve. Surgical results were also compared between patients with small aortic annulus and those with normal-sized aortic annulus. Using Doppler echocardiography, pressure gradients (PG), cardiac index (CI), effective orifice area (EOA), and performance index (PI) were calculated at rest and during stress. The mean body surface area (BSA) of patient who had undergone AVR with SJM19A, 19HP and 21A was 1.40, 1.42 and 1.56 m2, respectively. With dobutamine stress, heart rates, PG and CI increased significantly. Mean and maximum PG of patients with 19HP (8.0 and 15.4 mmHg at rest, 12.9 and 28.0 mmHg under stress, respectively) and 21A (9.5 and 19.1 mmHg at rest, 16.5 and 35.3 mmHg under stress, respectively) were relatively low. EOA index (EOAI) of patient with 19HP showed the highest values mean 0.93 cm2/m2. PIs tended to be higher with HP models than with standard models. The tests were completed without significant side effects such as frequent ventricular arrhythmias. Among the cases with small aortic annulus, there were no operative deaths or hospital deaths. There were also no late deaths, episodes of hemorrhage or thrombosis. Conclusions. In our institution, AVR was performed safely without any aortic annular enlargement with a small aortic anulus in small BSA patients. Postoperative hemodynamic data obtained by echocardiography were satisfactory for all patients at rest and even during maximum dobutamine stress test.     

主动脉瓣置换术后人工心脏瓣膜-病人不匹配现象

目的 探讨主动脉瓣置换术后人工心脏瓣膜-病人不匹配(PPM)现象的发生率以及PPM与术后早期血流动力学和病死率的关系.方法 292例主动脉瓣置换手术(AVR)病人,参照人工瓣膜有效开口面积(EOA)和病人的体表面积计算有效开口面积指数(EOAI),EOAI＞0.85 cm2/m2不存在或仅有轻度的PPM;中度PPM 0.65≤EOAI≤0.85 cm2/m2;重度PPM EOAI＜0.65 cm2/m2.超声多普勒测量AVR术后主动脉瓣位平均跨瓣压差和血流速度,比较不同种类瓣膜(机械瓣和生物瓣)和不同大小瓣膜(＞21 mm和≤21 mm)AVR术后PPM发生率以及PPM与术后早期血流动力学、病死率的关系.结果 292例中机械瓣置换术219例,生物瓣置换术73例,两种术后中度PPM发生率分别为6.25%和48.22%(P＜0.01).置换＞21 mm人工瓣膜(191例)和≤21 mm人工瓣膜(101例)术后PPM发生率分别为13.61%和33.66%(P＜0.05).PPM组术后主动脉瓣平均跨瓣压差和平均流速[(26.50±6.25)mm Hg(1 mm Hg=0.133 kPa)和(2.66±0.87)m/s]显著高于非PPM组[(16.75±3.46)mm Hg和(1.58±0.47)m/s,P＜0.01].PPM组和非PPM组的术后早期病死率分别为6.67%和2.16%(P＜0.05).结论 AVR术后PPM现象普遍存在,尤其是置换生物瓣以及小瓣膜(≤21 mm)者.PPM影响术后瓣膜血流动力学,与术后早期病死率密切相关.     

Hernodynamic Performance of the St. Jude Medical Hemodynamic Plus Valve

Abstract: The hemodynamic performance of the St. Jude Medical Hemodynamic Plus valve (HP) for a small aortic annulus was compared to that of the standard St. Jude Medical valve (SJM). Doppler echocardiographic parameters were evaluated in patients undergoing aortic valve replacement with either a 19 mm HP (HP19, n = 71, a 21 mm HP (HP21, n = S), a 19 mm SJM (SJM19, n = 16), or a 21 mm SJM (SJM21, n = 34). The peak and mean pres sure gradients and peak flow velocity were significantly (p < 0.05) lower in both patients with the HP21 and those with the HP19 than patients with the SJM21 and those with the SJM19, respectively. The echocardiographic parameters of the patients with the HP19 corresponded closely to those of patients with the SJM21. The left ventricular mass index regressed markedly in patients with the HP19 during the late postoperative period. The results suggested that the hemodynamic performances of certain sizes of the HP were superior to those of the same sue SJMs and were considered to be equivalent to those of the next size larger SJM.     

Avoidance of patient-prosthesis mismatch

To minimize the incidence of patient-prosthesis mismatch (PPM), we have routinely adopted aortic root enlargement to avoid PPM for patients with small aortic annulus. The aim of this study was to review our strategy of avoiding PPM. The Carpentier-Edwards Perimount (CEP) valves were implanted in 53 patients who were mostly aged over 65 and the St. Jude Medical (SJM) mechanical valves were used in 128 patients aged under 65. A standard 21-mm SJM valve was used in only 3 patients and no 19-mm valves were employed. However, 19-mm CEP valves were used in 12 patients with a small body surface area (1.43 +/- 0.14 m2). Of these, 26 patients (14.4%) who had a small aortic annulus and 24 patients aged under 65 underwent aortic root enlargement. No patient receiving an SJM valve had an projected indexed effective orifice area (EOAI) < or = 0.85 cm2/m2 because of performing aortic valve replacement (AVR) with annular enlargement and only 2 (3.8%) out of 53 patients receiving CEP valves developed PPM. Consequently, the prevalence of PPM was 1.1% in this series. The prevalence of PPM was low in patients over 65 years old with a relatively small body size who received bioprosthetic valves. A pericardial bioprosthesis was considered to be an appropriate valve in older population with regard to avoiding PPM. In patients under 65 years old with a small annulus, the first choice for avoiding PPM is aortic annular enlargement, which may be avoided by high performance mechanical valves with larger EOA.     

Initial in vivo results of the new Medtronic Advantage(TM) bileaflet valve in aortic position and comparison to the SJM

The present study investigated the Medtronic Advantage (MA) bileaflet valve in an animal model and compared the results to the St. Jude Medical (SJM) valve. Systolic performance and coronary artery flow in different orientations were studied.A rotation device holding either a MA or SJM aortic valve size 23 mm was implanted into eight pigs. Transvalvular pressure gradients and ventricular dimensions were investigated with the valves in different orientations. Coronary artery flow was measured at normal and high cardiac output.Orientation significantly influenced the hemodynamic performance of both valves. The best results for both valves were obtained with one orifice proximal to the right cusp. Pressure gradients and ventricular dimensions of the MA corresponded to the SJM. Coronary artery flow was higher for the MA.The systolic performance of the new MA bileaflet valve was similar to the SJM. During diastole, the MA showed significantly higher LAD coronary flow.     

液氮保存同种带支架人工瓣膜流体力学测试

目的：利用脉动流模拟实验装置测试液氮保存同种带支架瓣膜流体力学性能，同时与国产perfect牛心包人工瓣膜对比研究。方法：采集同种瓣膜，缝制成21^#、23^#、25^#同种带支架主动脉和同种带支架肺动脉人工瓣膜，经液氮保存，使用国产脉动流实验装置测试瓣膜流体力学性能，采用ISO／FDA浮估标准，分别测量各流量下的跨瓣压差、有效瓣口面积(EOA)和回流比。并与相应型号国产perfect牛心包人工瓣膜对比研究。结果：21^#、23^#、25^#同种带支架主动脉和肺动脉瓣膜的跨瓣压差和回流百分比差异无显著性，但较perfect瓣大。同种带支架主、肺动脉瓣膜的EOA差异无显著性，但较perfect牛心包生物瓣膜的略小些。同种带支架瓣膜实际开口面积(AOA)小于perfect牛心包瓣，但有效瓣口面积，实际开口面积比值无差别。结论：同种带支架主动脉和肺动脉人工瓣膜流体力学性能满意，同种带支架主动脉瓣膜与同种带支架肺动脉瓣膜流体力学性能无差别。     

Influence of St. Jude medical valve in patients with aortic stenosis and small aortic annulus on cardiac function and late survival result

This clinical study analyzes our experience of postoperative cardiac function and long-term survival rate in patients with aortic stenosis and small-size St. Jude Medical (SJM) valve. Sixty-eight patients who underwent aortic valve replacement by SJM valve were divided into two groups by preoperative aortic annulus diameter. Group 1 consisted of 44 patients with small aortic annulus and small-size SJM valve (19 mm or 21 mm). In Group 1, small SJM standard valves were implanted in 16 patients, and small SJM Hemodynamic Plus (HP) valves were implanted in 28 patients. Group 2 consisted of 24 patients with large-size SJM standard valve (23 mm or larger). Preoperative left ventricular mass index, left ventricular dimension, the dimension of ascending aorta, and body surface area were significantly smaller in Group 1 than in Group 2. Average age at surgery was older in Group 1 than in Group 2. Effective orifice area index of the SJM valve measured by the manufacturer's data was smaller in Group 1 than in Group 2. Postoperative left ventricular mass indexes of Group 1 (standard valve or HP valve) and Group 2 significantly decreased in comparison with the preoperative mass indexes. Postoperative left ventricular ejection fraction and the peak ejection rate of Group 1 were not different from those of Group 2. The 10 year survival rate of Group 1 was 79%, and the rate of Group 2 was 77%. At 10 years after surgery, freedom from valve-related complication of Group 1 was 80%, and freedom from complication of Group 2 was 81%. Our results demonstrated that small-size SJM valve afforded satisfactory long-term survival rate and valve-related event-free rate for elderly patients with small body surface area and small aortic annulus.     

Evaluation of St. Jude Medical valve's long-term function by Doppler echocardiography.

In this study, the long-term function of St. Jude Medical valve (SJM valve) is evaluated by Doppler echocardiography. The subjects were 191 patients who underwent mitral or aortic valve replacement using SJM valve in our institute since July 1978 and had no clinical problem showing more than 50% of left ventricular ejection fraction. The patients were classified into 3 groups according to measurement period (within 5 years, 10 years and 15 years and more), and further classified by size and their results were compared. In every group by size, there was no significant difference among groups by measurement period. In the mitral valve position, peak pressure gradient and pressure half-time were not significantly different among groups by size. On the other hand, in the aortic valve position, pressure gradient in 21-mm group was significantly high among 21-mm, 25-mm, and 27-mm groups, showing a negative correlation with size. As the result, it was suggested that SJM valve kept a good function more than 15 years after operation. From these results, it was considered that the patients with small annlus of the aortic valve needed annulus-enlarging procedure or use of Hemodynamic Plus series valves to keep the size of more than 23 mm.     

The evaluation of pressure gradients of various aortic valve prostheses by Doppler ultrasound and influence of pressure gradients to left ventricular function

Although the pressure gradients of heart valve prostheses has been discussed over the years, currently available valve prostheses are still not sufficient and may leave pressure gradients following aortic valve replacement. The selection of valve prosthesis and its size is still controversial. This study is aimed to measure the pressure gradients of 64 aortic valve prostheses noninvasively by means of doppler ultrasound and determine which size and what kind of valve prosthesis is suitable for aortic valve replacement. 1. Pressure gradients and LV function were serially assessed pre- and post operatively. Left ventricular mass index regressed to a normal range and the response to exercise test is quite satisfactory in the patients whose pressure gradients were less than 25 mmHg. In the cases that showed pressure gradients more than 25 mmHg, however, left ventricular hypertrophy significantly remained even 5 years after aortic valve replacement and the response to exercise was not good enough. From these results, it is concluded that the upper limit of acceptable pressure gradients is 25 mmHg in aortic valve prosthesis. 2. The pressure gradients of St. Jude Medical (SJM) valve (11 cases), Bj?rk-Shiley (B-S) valve (7 cases), Lillehei-Kaster (L-K) valve (13 cases) and Omniscience (O-S) valve (33 cases) was evaluated to compare the hemodynamic characteristics in the long term follow-up periods. In SJM and B-S, a correlation between valve area index (geometrical valve orifice area/body surface area) and pressure gradients was significant. The valve area index more than 1.4 cm2/m2 in SJM or more than 1.7 cm2/m2 in B-S should be selected. Whereas for L-K and O-S, a correlation between valve area index and pressure gradients was not significant and it is suggested that his is due to suboptimal disc opening angle (L-K; 54 degree on the average, O-S; 46 degree on the average). For this reason, the use of these prostheses is not recommended for choice in the aortic position.     

Case report of a malfunctioning SJM 19 A aortic valve prosthesis requiring reoperation

The patient was a 56-year-old female diagnosed with poor lung function who had undergone an aortic valve replacement 10 years ago, receiving an SJM 19 A prosthetic valve. She suffered from dyspnea and chest pain with postural change. Her anticoagulation level was maintained therapeutic. A cinefluoroscopy showed that one of the leaflets in the prosthetic valve was not moving. The aortic peak pressure gradient was calculated to be 68 mmHg using Doppler echocardiography. The patient's clinical condition improved after thrombolytic therapy with urokinase, but a complete normalization of her prosthetic discs was not obtained, so the patient was treated surgically. After an aortotomy, a pannus formation covering the entire SJM 19 A valve was observed. The aortic annulus was estimated to be 16 mm in diameter after the excision of the SJM 19 A valve and required before a larger prosthesis could be inserted. A SJM 19 HP valve was then anchored to the enlarged annulus. Her postoperative course was uneventful. We report a case requiring reoperation after a small aortic mechanical valve prosthesis implanted 10 years previously was damaged by thrombosis and pannus. Pannus formation on small aortic prosthesis easily caused hemodynamic obstructions and mechanical failure. Intensive evaluation with Doppler echocardiography and cinefluoroscopy is required for such patients.     

A case of aortic valve replacement with St. Jude Medical Regent valve (first implant in Japan).

The St. Jude Medical (SJM) Regent valve was developed as a new mechanical valve by improving the conventional SJM valve. The effective orifice area is wider than that of Hemodynamic Plus (HP) series. The efficacy of the new valve has been reported in Europe and the United States. On October 26, 2004, we first performed aortic valve replacement (AVR) with the SJM Regent valve for aortic valve stenosis in Japan. A 64-year-old female was admitted to our hospital with dyspnea on exertion. She was diagnosed with aortic valve stenosis. She underwent AVR with a 17 mm SJM Regent valve. According to the results of echocardiography conducted two months postoperatively, the peak pressure gradient of the prosthetic valve was 32.0 mmHg, the mean pressure gradient was 13.2 mmHg, and the effective orifice area index (EOAI) was 0.92 cm2/m2. Cinefluoroscopy showed the valve opening angle of 85 degrees indicating full opening. She was discharged 15 days after surgery without complications. As demonstrated by the present case, implantation of a 17 mm SJM Regent valve produced a satisfactory result reflected by lower pressure gradient and absence of patient-prosthetic mismatch. In the future, the new valve is expected to be the optimum mechanical valve for a narrow annulus.     

The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance

This study compares the implantation characteristics and the hemodynamic performance of the new Carpentier-Edwards Perimount Magna (CEPM) xenograft with those of the standard Perimount (CEPS) valve in the aortic position. Eighty consecutive patients surviving an aortic valve replacement with either the CEPS valve (n=40) or the CEPM prosthesis (n=40) in the supra-annular position were retrospectively reviewed. One year follow-up was complete and hemodynamic performance assessed by Doppler echocardiography. The mean valve size implanted was 21.3+/-1.7 mm (CEPS) vs. 22.2+/-1.8 mm (CEPM). The average mean pressure gradient was 13.6+/-5.1 mmHg in the CEPS group and 9.6+/-3.3 mmHg in the CEPM group (P<0.0001). Mean and peak gradients were slightly lower and the effective orifice areas (EOA) were larger for the Magna prosthesis than for the comparable standard valves: 19 mm (1.58+/-0.2 vs. 1.28+/-0.1 cm(2)), 21 mm (1.90+/-0.4 vs. 1.69+/-0.4 cm(2)), 23 mm (2.07+/-0.3 vs. 1.86+/-0.3 cm(2)), 25 mm (2.30+/-0.1 vs. 1.89+/-0.5 cm(2)). The average indexed EOA was statistically different between groups (CEPS 0.98+/-0.21 cm(2)/m(2) vs. CEPM 1.20+/-0.25 cm(2)/m(2)). Patient-prosthesis mismatch (indexed EOA相似文献   

Mass regression in aortic stenosis after valve replacement with small size pericardial bioprosthesis

BACKGROUND: The aim of the study was to determine whether left ventricular mass regression is influenced by valve size after the implantation of a Carpentier-Edwards Perimount (CEP) pericardial bioprosthesis for pure aortic stenosis. METHODS: Patients receiving 19-mm, 21-mm, and 23-mm CEP aortic valves underwent echocardiography preoperatively and at least 1 year after surgery (mean, 2.3 +/- 1 years) and the echocardiograms were compared within and between groups. RESULTS: The study involved a total of 88 patients: 34 receiving 19-mm CEPs, 29 receiving 21-mm CEPs, and 25 receiving 23-mm CEPs. The mean postoperative prosthetic gradients were respectively 20.6 +/- 6.6 mm Hg, 17.9 +/- 5.8 mm Hg, and 13.2 +/- 4.1 mm Hg (p = 0.0001); the mean postoperative valve areas were respectively 1.24 +/- 0.16 cm(2), 1.45 +/- 0.2 cm(2), and 1.63 +/- 0.21 cm(2) (p = 0.0001). In comparison with the preoperative echocardiographic measurements absolute left ventricular mass significantly decreased by -54.1 +/- 48.8 g, -54.1 +/- 55.1 g, and -74.4 +/- 57.4 g respectively with no statistically significant between-group difference (analysis of variance) but ventricular septum and posterior wall thickness significantly decreased in each group (p < 0.05). CONCLUSIONS: The implantation of 19-mm, 21-mm, and 23-mm CEP aortic prostheses significantly reduces left ventricular mass without any size-related differences.     

Trans-catheter valve-in-valve implantation: in vitro hydrodynamic performance of the SAPIEN + cloth trans-catheter heart valve in the Carpentier-Edwards Perimount valves

Objective: Since 1990, over 1.2 million bioprosthetic valves were implanted for aortic stenosis. Given the risk of structural valve deterioration, the need to redo AVR will likely rise. Recently, SAPIEN valve-in-valve (ViV) has been advocated. We evaluated the in vitro hydrodynamic performance of the Edwards SAPIEN + cloth trans-catheter heart valve (THV) implanted within the Carpentier-Edwards Perimount (CEP) valve. Methods: Both 23- and 26-mm Edwards SAPIEN + cloth THVs (Model 9000MIS) were deployed within 23- or 25-mm (1) CEP aortic bioprosthesis (Models 2700 and 2800), (2) CEP Magna (Model 3000), and (3) CEP plus pericardial mitral (Model 6900P), respectively. Tests included: (1) mean pressure gradient; (2) pulsatile effective orifice area (EOA); (3) regurgitant volume; (d) migration during accelerated wear testing (AWT; 20 million cycles @ 200 mmHg); and (5) valve dislodgement pressure. Values tested per ISO 5840:2005 valve standards; mean ± SD. Results: Post-deployment pressure gradient across the combined valves ranges from 2.8 ± 0.3 to 8.7 ± 0.5 mmHg. The post-deployment EOA of the valves ranged from 1.7 ± 0.1 to 2.0 ± 0.0 cm². Pulsatile flow regurgitant volume ranged from 2.1 ± 0.7 to 7.6 ± 1.2 ml. Migration during the AWT ranged from 0.01 ± 0.27 to 1.61 ± 0.92 mm. Pressure increase during the tests to quantify migration ranged from >400 to >800 mmHg. Conclusions: Compared with the rigorous ISO 5840:2500 valve standards, the Edwards SAPIEN + cloth THV implanted ViV within the CEP valve demonstrated excellent hydrodynamic performance.     

Stentless bioprosthesis for aortic valve replacement

The stentless aortic bioprosthesis was reported to reduce left ventricular mass (LVM) in the early period after implantation and have better hemodynamic performance and a larger effective orifice area (EOA) than stented valves. However, its clinical advantage over the stented valve is still unclear. We have implanted stentless bioprostheses in 61 patients and had a low operative mortality rate (1.6%). LVM index, left ventricular end-diastolic volume (LVEDV) index, left ventricular end-systolic volume (LVESV) index, and peak pressure gradient (PG) were rapidly reduced after implantation. Ten-year-freedom from cardiac-related death, thromboemolism, and structural valve deterioration rates were 91.0%, 100%, and 95.0%, respectively. Furthermore, using MRI analysis, blood velocity through stentless valves was similar to that through native aortic valves in comparison with stented valves. In conclusion, the stentless valve enables more physiologic blood flow through the valve, and thus it may be useful in patients with small annuli or those who require better hemodynamic performance to enable physical activity.     

Selection of a prosthetic valve for mitral valve replacement

The early and the late results of mitral valve replacement were retrospectively evaluated to delineate the concept of selection of the prosthetic valve for the mitral position. The mitral valve was replaced with porcine bioprosthesis (P-B) in 102 patients and with St. Jude Medical prosthesis (SJM) in 341 patients between 1975 and 1987. Operative mortality was 5.3% for the SJM and 8.8% for the P-B group (N.S.). Cumulative duration of follow up was 1479.8 patient-years for the SJM and 888.9 patient-years for the P-B group. Actuarial survival rate was 90% for the SJM at 9 years and 81%, 76% for the P-B group at 10 and 13 years (N.S.). Freedom from valve-related death was 94% for the SJM at 9 years and 94% for the P-B at 13 years (N.S.). Thrombo-embolic complications occurred at an incidence of 0.47%/patient-years (p-y) for the SJM and 0.67%/p-y for the P-B group (N.S.). Freedom from prosthetic valve dysfunction due to primary tissue failure (PTE) lowered rapidly after the seventh postoperative year from 88% to 35% in the P-B group. Prosthetic valve dysfunction free rate was significantly lower in the P-B group compared with the SJM between the seventh post operative year and ninth postoperative year (p less than 0.01). From this analysis, we believe that the SJM prosthesis is suitable cardiac valve prosthesis to the mitral position.     

The St. Jude "Silzone" valve: midterm results in treatment of active endocarditis

BACKGROUND: The Silzone-coated St. Jude Medical valve (SJM "Silzone" valve), developed to reduce prosthetic valve endocarditis (PVE), was recalled by SJM due to a higher rate of paravalvular leaks. The aim of this study was to determine the efficacy of the SJM "Silzone" valve in avoiding PVE and to evaluate the frequency of paravalvular leaks, when the valve was used exclusively for active bacterial endocarditis. METHODS: From January 1998 to December 1999, the SJM "Silzone" valve was implanted in 40 consecutive patients with active endocarditis (20 aortic, 14 mitral, and 6 both valves). Late transesophageal echocardiography was performed in 87% of survivors, and transthoracic echocardiography in the remaining 13%. Follow-up was 100%. RESULTS: Hospital mortality was 17.5%. Early PVE occurred in 2 of 40 patients (5%). There were two late deaths without signs of recurrent PVE. A hemodynamic relevant paravalvular leak necessitating reoperation was seen in 2 patients within 6 months after operation. The rate of a minor paravalvular leak was 13% (4 of 31 patients). CONCLUSIONS: The SJM "Silzone" valve when implanted for active bacterial endocarditis does not give better results than other mechanical prostheses with regard to early recurrence of endocarditis. The rate of a hemodynamic relevant paravalvular leak requiring reoperation seems rather high during the early postoperative period, whereas the occurrence of minor paravalvular leaks is comparable with that of other mechanical prostheses. Routine observation, recommended for all patients with mechanical heart valves, is also sufficient for patients with the SJM "Silzone" valve.     

Clinical evaluation of ATS prosthetic valve by doppler echocardiography: comparison with St. Jude Medical (SJM) valve.

ATS valve is a bileaflet valve developed to have a superior function to traditional prosthetic valves on anti-thrombogenesis and hemolysis. The orifice area was enlarged in consequence of making its orifice with pyrolytic carbon materials, and the pivot was open pivot and the strut was eliminated. The efficiency of this valve has been reported in the Europe. In Japan, its clinical trial was performed in September 1993 and its clinical use was permitted in August 1996. In this study, we compared the functions of ATS and St. Jude Medical (SJM) valves with echocardiography. The pressure gradients at the mitral valve position were not significantly different between ATS and SJM valves, but that of ATS was lower than that of SJM. The pressure gradient at the aortic valve position of ATS was also lower than that of SJM, and especially those of the patients who performed aortic valve replacement with 23-mm ATS and SJM valves were 8.9+/-1.6 and 23.3+/-6.6 mmHg, showing a significant difference. Though further observation and review of this valve are needed at the chronic phase, ATS valve is an excellent bileaflet valve on the valvular function, showing a low pressure gradient.     

Comparative analysis of Hancock and St. Jude Medical valve after mitral valve replacement]

Long term results were compared in 81 operative survivors with MVR using Hancock valve (Hancock group) and 83 using St. Jude Medical valve (SJM group). The cumulative follow-up was 709.0 patients-year (p-y) and 175.2 p-y in the Hancock and SJM groups. Twenty-four percent of the patients in the Hancock group was permanently anticoagulated, while 100% of patients in the SJM group anticoagulated. The 7-year actuarial survival rate including early mortality was 79.3 +/- 4.6% for the Hancock and 93.9 +/- 3.0% for the SJM group (p less than 0.01). The survival rate was significantly higher in the SJM group than that in the Hancock group. The 7-year actuarial event free rate of the valve-related complications in the Hancock and SJM groups were as follows; thromboembolism 88.6 +/- 3.8% vs 95.0 +/- 2.8% (NS), hemorrhage, 94.0 +/- 3.0% vs 98.7 +/- 1.8% (NS), paravalvular leak 92.6 +/- 3.2% vs 97.4 +/- 1.8% (NS), infection 93.9 +/- 3.0% vs 100% (p less than 0.05), valve malfunction 78.0 +/- 5.2% vs 100% (p less than 0.001), overall valve related complications 58.9 +/- 5.9% vs 91.1 +/- 3.5% (p less than 0.001), reoperation for valve-related complication 83.1 +/- 4.6% vs 100% (p less than 0.01). The event free rate of reoperation for valve related complication in the Hancock group was significantly lower than that in the SJM group. The Hancock valve had the acceptable antithrombogenicity, but had the limited long-term durability.(ABSTRACT TRUNCATED AT 250 WORDS)